Reihl, Sheantel J
Mayo Clinic
University of California, San Francisco
Citations 2
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning
Mehari, Mulki , Warrier, Gayathri , Dada, Abraham , Kabir, Aymen , Haskell-Mendoza, Aden , Tripathy, Arushi , Jha, Rohan , Nieblas‐Bedolla, Edwin , Jackson, Joshua , Gonzalez, Ariel T , Reason, Ellery , Flusché, Ann Marie , Reihl, Sheantel , Dalton, Tara , Negussie, Mikias , Gonzales, Cesar Nava, Ambati, Vardhaan , Desjardins, Annick , Krishna, Saritha, Chang, Susan M. , Porter, Alyx B. , Fecci, Peter E. , Hollon, Todd , Chukwueke, Ugonma , Badal, Kimberly , Molinaro, Annette M. , Hervey‐Jumper, Shawn L. , Haskell-Mendoza, Aden P , Reason, Ellery H , Ambati, Vardhaan , Krishna, Saritha , Porter, Alyx , Hollon, Todd , Chukwueke, Ugonma N , Badal, Kimberly , Molinaro, Annette M. , Hervey-Jumper, Shawn L , Reihl, Sheantel J , Fecci, Peter E , Desjardins, Annick , Daniel, Andy G. S.
Science Advances | June 11, 2025 | Volume: 11 | Issue: 23 | Pages: No page available
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.
A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act
Reihl, Sheantel , Patil, Nirav , Morshed, Ramin A, Mehari, Mulki, Aabedi, Alexander, Chukwueke, Ugonma N, Porter, Alyx B, Fontil, Valy , Cioffi, Gino, Waite, Kristin, Ostrom, Quinn, Barnholtz-Sloan, Jill, Hervey‐Jumper, Shawn L. , Ostrom, Quinn T. , Morshed, Ramin A. , Reihl, Sheantel J , Kruchko, Carol , Hervey-Jumper, Shawn L , Morshed, Ramin , Patil, Nirav , Mehari, Mulki, Aabedi, Alexander, Chukwueke, Ugonma N, Porter, Alyx B, Fontil, Valy , Cioffi, Gino, Waite, Kristin, Barnholtz-Sloan, Jill, Ostrom, Quinn T
Neuro-Oncology | January 5, 2022 | Volume: 24 | Issue: 8 | Pages: 1341-1349
Abstract Background The NIH Revitalization Act, implemented 29 years ago, set to improve the representation of women and minorities in clinical trials. In this study, we investigate progress made in all phase therapeutic clinical trials for neuroepithelial CNS tumors stratified by demographic-specific age-adjusted disease incidence and mortality. Additionally, we identify workforce characteristics associated with clinical trials meeting established accrual benchmarks. Methods Registry study of published clinical trials for World Health Organization defined neuroepithelial CNS tumors between January 2000 and December 2019. Study participants were obtained from PubMed and ClinicalTrials.gov. Population-based data originated from the CBTRUS for incidence analyses. SEER-18 Incidence-Based Mortality data was used for mortality analysis. Descriptive statistics, Fisher exact, and χ 2 tests were used for data analysis. Results Among 662 published clinical trials representing 49 907 participants, 62.5% of participants were men and 37.5% women (P < .0001) representing a mortality specific over-accrual for men (P = .001). Whites, Asians, Blacks, and Hispanics represented 91.7%, 1.5%, 2.6%, and 1.7% of trial participants. Compared with mortality, Blacks (47% of expected mortality, P = .008), Hispanics (17% of expected mortality, P < .001) and Asians (33% of expected mortality, P < .001) were underrepresented compared with Whites (114% of expected mortality, P < .001). Clinical trials meeting accrual benchmarks for race included minority authorship. Conclusions Following the Revitalization Act, minorities and women remain underrepresented in therapeutic clinical trials for neuroepithelial tumors, relative to disease incidence and mortality. Study accrual has improved with time. This study provides a framework for clinical trial accrual efforts and offers guidance regarding workforce considerations associated with enrollment of underserved patients.